Page 190 - 2021_06-Haematologica-web

R.D. Jachimowicz et al.
Contributions
RDJ, AP, HH, SR, AE and WK designed the research. RDJ, LP, SR, AG, AP, HH, LF, FF, MO, FJ, CT, MLH, PM, AR, HS, HCR, PB, BvT, AE and WK collected and assembled the data. RDJ, SR, AP, AE and WK analyzed and interpreted the data. RDJ and WK wrote the first draft and all authors approved the paper.
Acknowledgments
The authors thank all patients enrolled in GHSG clinical trials,
all clinicians and pathologists supporting the clinical trials and the translational research program of the GHSG.
Funding
This work was supported by a grant from German Cancer Aid (Deutsche Krebshilfe n. 70112502), the Else Kröner-Fresenius Stiftung (2016-Kolleg-19 to RDJ) and the Stiftung Kölner Krebsforschung (to RDJ). Image analysis software was supported by the Kinderkrebsinitiative Buchholz, Holm-Seppensen.
References
1. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP- ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-2395.
2. Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a popula- tion-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012; 119(4):990-996.
3.Goodman KA, Riedel E, Serrano V, et al. Long-term effects of high-dose chemothera- py and radiation for relapsed and refractory Hodgkin's lymphoma. J Clin Oncol. 2008;26(32):5240-5247.
4. Eichenauer DA, Engert A, Andre M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii70-75.
5. Aoki T, Steidl C. Novel biomarker approach- es in classic Hodgkin lymphoma. Cancer J. 2018;24(5):206-214.
6. Condeelis J, Pollard JW. Macrophages: obli- gate partners for tumor cell migration, inva- sion, and metastasis. Cell. 2006;124(2):263- 266.
7. Vassallo J, Metze K, Traina F, et al. Further remarks on the expression of CD20 in clas- sical Hodgkin's lymphomas. 2002;87(3): ELT17.
8. Rassidakis GZ, Medeiros LJ, Viviani S, et al. CD20 expression in Hodgkin and Reed- Sternberg cells of classical Hodgkin's dis- ease: associations with presenting features and clinical outcome. J Clin Oncol. 2002;20(5):1278-1287.
9. Aldred V, Vassallo J, Froes MCAH, Augusto Soares F. CD20 expression by Hodgkin- Reed-Sternberg cells in classical Hodgkin lymphoma is related to reduced overall sur- vival in young adult patients. Leuk Lymphoma. 2008;49(11):2198-2202.
10.Portlock CS, Donnelly GB, Qin J, et al. Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. Br J Haematol. 2004;125(6):701-708.
11. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica. 2011;96(2):186-189.
12. Steidl C, Lee T, Shah SP, et al. Tumor-associ- ated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010;362(10):875-885.
13. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor
macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010;77(6):301-308.
14. Kamper P, Bendix K, Hamilton-Dutoit S, et al. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lym- phoma. Haematologica. 2011;96(2):269-276.
15.Panico L, Ronconi F, Lepore M, et al. Prognostic role of tumor-associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma. 2013;54(11):2418-2425.
16.Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood. 2009;113(12):2765-3775.
17.Greaves P, Clear A, Coutinho R, et al. Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classi- cal Hodgkin lymphoma is predictive of out- come. J Clin Oncol. 2013;31(2):256-262.
18. Tudor CS, Distel LV, Eckhardt J, et al. B cells in classical Hodgkin lymphoma are impor- tant actors rather than bystanders in the local immune reaction. Hum Pathol. 2013;44(11):2475-2486.
19. Borchmann P, Haverkamp H, Diehl V, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of base- line-dose BEACOPP with or without radio- therapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234-4242.
20.Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET- guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799.
21.Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, inter- national, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2018;390(10114):2790-2802.
22. Hutchings M, Loft A, Hansen M, et al. FDG- PET after two cycles of chemotherapy pre- dicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-59.
23.Scott DW, Chan FC, Hong F, et al. Gene expression-based model using formalin- fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical
Hodgkin lymphoma. J Clin Oncol. 2013;31
(6):692-700.
24.Tan KL, Scott DW, Hong F, et al. Tumor-
associated macrophages predict inferior out- comes in classic Hodgkin lymphoma: a cor- relative study from the E2496 Intergroup trial. Blood. 2012;120(16):3280-3287.
25. Azambuja D, Natkunam Y, Biasoli I, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lym- phoma. Ann Oncol. 2012;23(3):736-742.
26. Sanchez-Espiridion B, Martin-Moreno AM, Montalban C, et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica. 2012;97(7): 1080-1084.
27. Diefenbach CS, Li H, Hong F, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015;171 (4):530-538.
28. Guisado-Vasco P, Arranz-Saez R, Canales M, et al. Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series. Leuk Lymphoma. 2012;53(5):812-819.
29. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood. 2006;108(2):662-668.
30. Panico L, Tenneriello V, Ronconi F, et al. High CD20+ background cells predict a favorable outcome in classical Hodgkin lym- phoma and antagonize CD68+ macrophages. Leuk Lymphoma. 2015;56(6): 1636-1642.
31. Sanchez-Espiridion B, Montalban C, Lopez A, et al. A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 2010;116(8): e12-17.
32. Griss J, Bauer W, Wagner C, et al. B cells sus- tain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat Commun. 2019;10(1):4186.
33.Cader FZ, Schackmann RCJ, Hu X, et al. Mass cytometry of Hodgkin lymphoma reveals a CD4(+) regulatory T-cell-rich and exhausted T-effector microenvironment. Blood. 2018;132(8):825-836.
34. Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1- associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420-2430.
1692
haematologica | 2021; 106(6)